

ACS Cancer Conference 2025

March 12-14 | Phoenix, AZ

ACS **CRP**

Cancer Research Program
American College of Surgeons

National Cancer Database Annual Report

Courtney N. Day MS

Senior Biostatistician

Mayo Clinic, Rochester, MN

ACS **Cancer Programs**
American College of Surgeons



Disclosures

- No relevant financial disclosures
- The National Cancer Database (NCDB) is a joint project of the Commission on Cancer (CoC) of the American College of Surgeons and the American Cancer Society. The CoC's NCDB and the hospitals participating in the CoC's NCDB are the source of the de-identified data used herein; they have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors.

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Aim

Disseminate a series of regular reports from the NCDB to include:

Primary site-specific overviews of cases

Demographics

Facility information

Outcomes

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Aim

Allows for broader access to NCDB participant user file (PUF) contents through publishing in a peer reviewed journal information that was previously only available to Commission on Cancer (CoC) participating facilities

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

American College of Surgeons Cancer Program Annual Report from 2021 Participant User File

Elizabeth B Habermann, PhD, MPH, Courtney N Day, MS, Bryan E Palis, MA, Jennifer K Plichta, MD, FACS, Nabil Wasif, MD, FACS, Ronald J Weigel, MD, FACS, PhD, MBA, Judy C Boughey, MD, FACS

Primary tumor site in depth review


Breast

Colon

Pancreas

Overview of the 2021 NCDB Adult Participant User File

CoC Accredited Hospitals



Hospital registry data
collected from 1,500+
CoC-accredited
facilities

more than 40 million
historical records

Palis et al, ASO, 2024; 31:5546-5559
American College of Surgeons National Cancer Database tools
American College of Surgeons National Cancer Database participant user file overview
American College of Surgeons National Cancer Database participant user file
Habermann et al, JACS 2025; 240(1):95-110

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Overview of the 2021 NCDB Adult Participant User File (PUF)

- NCDB cases comprise an estimated proportion of 73.7% of all cancer cases in the United States
 - Ranges from 49.5-89.1% across cancer sites
- Overall total number of cases in 2021 Adult PUF – 21,049,377
 - 1,328,131 added in 2021 alone
- In 2021, the NCDB's five most common cancers in adults were:
 - Breast
 - Prostate
 - Lung Bronchus – Non-Small Cell Carcinoma
 - Colon
 - Melanoma of Skin

Palis et al, ASO, 2024; 31:5546-5559
American College of Surgeons National Cancer Database tools
American College of Surgeons National Cancer Database participant user file overview
American College of Surgeons National Cancer Database participant user file
Habermann et al, JACS 2025; 240(1):95-110

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

	All Sites (N=1,328,131)
Age at Diagnosis, Median (Q1,Q3)	66.0 (57.0, 74.0)
Sex	
Male	607031 (45.7%)
Female	721100 (54.3%)
Race/Ethnicity	
White	1005778 (76.6%)
Black	151139 (11.5%)
Asian	47888 (3.6%)
Native Hawaiian/Pacific Islander	3392 (0.3%)
American Indian/Alaskan Native	5731 (0.4%)
Spanish/Hispanic	78608 (6.0%)
Other	20616 (1.6%)
Unknown	14979
Charlson-Deyo Score	
0	954767 (71.9%)
1	211875 (16.0%)
2	83196 (6.3%)
≥ 3	78293 (5.9%)
Primary Payor at Diagnosis	
Not Insured	26064 (2.0%)
Private Insurance	473423 (36.0%)
Medicaid	99712 (7.6%)
Medicare	689745 (52.5%)
Other Government	25622 (1.9%)
Unknown	13565

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.



Habermann et al, JACS 2025; 240(1):95-110

	All Sites (N=1,328,131)	Breast (N=264,095)	Prostate (N=138,266)	Lung, Bronchus - Non-Small Cell Carcinoma (N=122,491)	Colon (N=70,774)	Melanoma of the Skin (N=62,003)
Age at Diagnosis, Median (Q1,Q3)	66.0 (57.0, 74.0)	63.0 (53.0, 72.0)	67.0 (62.0, 73.0)	70.0 (63.0, 77.0)	68.0 (57.0, 78.0)	67.0 (57.0, 76.0)
Sex						
Male	607031 (45.7%)	2117 (0.8%)	NA	60154 (49.1%)	35361 (50.0%)	35946 (58.0%)
Female	721100 (54.3%)	261978 (99.2%)		62337 (50.9%)	35413 (50.0%)	26057 (42.0%)
Race/Ethnicity						
White	1005778 (76.6%)	193229 (74.0%)	101954 (74.7%)	97611 (80.3%)	51712 (73.9%)	59636 (97.1%)
Black	151139 (11.5%)	32482 (12.4%)	22245 (16.3%)	13954 (11.5%)	9244 (13.2%)	301 (0.5%)
Asian	47888 (3.6%)	13138 (5.0%)	3464 (2.5%)	4040 (3.3%)	2697 (3.9%)	144 (0.2%)
Native Hawaiian/Pacific Islander	3392 (0.3%)	820 (0.3%)	273 (0.2%)	238 (0.2%)	161 (0.2%)	46 (0.1%)
American Indian/Alaskan Native	5731 (0.4%)	1108 (0.4%)	422 (0.3%)	499 (0.4%)	327 (0.5%)	89 (0.1%)
Spanish/Hispanic	78608 (6.0%)	15971 (6.1%)	6170 (4.5%)	3980 (3.3%)	4653 (6.7%)	871 (1.4%)
Other	20616 (1.6%)	4211 (1.6%)	1937 (1.4%)	1206 (1.0%)	1174 (1.7%)	326 (0.5%)
Unknown	14979	3136	1801	963	806	590
Charlson-Deyo Score						
0	954767 (71.9%)	213660 (80.9%)	107794 (78.0%)	69402 (56.7%)	48022 (67.9%)	50833 (82.0%)
1	211875 (16.0%)	33314 (12.6%)	18611 (13.5%)	28372 (23.2%)	12373 (17.5%)	6855 (11.1%)
2	83196 (6.3%)	9947 (3.8%)	6517 (4.7%)	12889 (10.5%)	4998 (7.1%)	2355 (3.8%)
≥ 3	78293 (5.9%)	7174 (2.7%)	5344 (3.9%)	11828 (9.7%)	5381 (7.6%)	1960 (3.2%)
Primary Payor at Diagnosis						
Not Insured	26064 (2.0%)	3554 (1.4%)	1705 (1.2%)	2114 (1.7%)	1725 (2.5%)	711 (1.2%)
Private Insurance	473423 (36.0%)	122069 (46.6%)	48757 (35.6%)	25530 (21.0%)	23066 (32.9%)	25346 (41.3%)
Medicaid	99712 (7.6%)	17980 (6.9%)	5904 (4.3%)	9658 (8.0%)	5590 (8.0%)	2179 (3.6%)
Medicare	689745 (52.5%)	114909 (43.9%)	76355 (55.8%)	80917 (66.7%)	38683 (55.2%)	32047 (52.2%)
Other Government	25622 (1.9%)	3260 (1.2%)	4219 (3.1%)	3104 (2.6%)	980 (1.4%)	1094 (1.8%)
Unknown	13565	2323	1326	1168	730	626

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Habermann et al, JACS 2025; 240(1):95-110


Ten-year overall survival for the 5 most common solid tumors 2004 through 2020



© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Habermann et al, JACS 2025; 240(1):95-110

Neoadjuvant systemic therapy trends in surgical patients with the NCDDB top 10 most common cancers 2010-2021




© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Habermann et al, JACS 2025; 240(1):95-110

Breast Cancer PUF 2021

- In 2021, 264,095 adult cases reported by 1,276 NCDB-participating facilities.
- Represents an estimated **81.9%** of all breast cancers diagnosed in the US.
- The total number of breast cancer cases in the NCDB 2004-2021 is 3,956,621 cases.
- Median age at diagnosis was 63 years (IQR 53-72)
- 99.2% of cases were in women, 0.8% in men
- Other demographics
 - 74.0% White, 12.4% Black, 6.1% Spanish/Hispanic and 5.0% Asian
 - 46.6% Privately insured, 43.9% Medicare, and 6.9% Medicaid
- Treatment facility information
 - 40.5% Comprehensive community, 30.7% Academic/research, 21.7% Integrated network and 7.1% Community

Proportion of patients diagnosed with breast cancer 2004-2021



- Increase in early-stage disease from 2004-2021
- Slight decrease in advanced/metastatic disease from 2004-2021
- No significant change in anatomic stage of breast cancer at presentation from 2018-2021


© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Habermann et al, JACS 2025; 240(1):95-110

		2018 (N=254,151)	2019 (N=263,554)	2020 (N=235,443)	2021 (N=258,915)
Biomarker	ER+/HER2+	20173 (9.9%)	19438 (9.1%)	17621 (9.2%)	18101 (8.6%)
	ER+/HER2-	151029 (73.9%)	160276 (75.1%)	142903 (74.4%)	158368 (75.3%)
	ER-/HER2+	8624 (4.2%)	8745 (4.1%)	8204 (4.3%)	8793 (4.2%)
	ER-/HER2-	24438 (12.0%)	25079 (11.7%)	23379 (12.2%)	25014 (11.9%)
	Unknown	49887	50016	43336	48639
Tumor Grade	Grade 1	53903 (22.1%)	54472 (21.4%)	47338 (20.8%)	52205 (20.8%)
	Grade 2	112916 (46.3%)	121109 (47.5%)	108782 (47.8%)	122993 (49.0%)
	Grade 3 or 4	76856 (31.5%)	79131 (31.1%)	71382 (31.4%)	75718 (30.2%)
	Unknown	10476	8842	7941	7999
Histology	DCIS	37511 (14.8%)	40391 (15.3%)	34652 (14.7%)	39634 (15.3%)
	IDC	167967 (66.1%)	174954 (66.4%)	156284 (66.4%)	170024 (65.7%)
	ILC	22391 (8.8%)	23735 (9.0%)	21731 (9.2%)	24064 (9.3%)
	MIDLC	7521 (3.0%)	7626 (2.9%)	7049 (3.0%)	7960 (3.1%)
	Other	18761 (7.4%)	16848 (6.4%)	15727 (6.7%)	17233 (6.7%)

		2018 (N=173,926)	2019 (N=180,729)	2020 (N=160,404)	2021 (N=177,593)
Primary Surgery Type	None	5477 (3.2%)	6047 (3.4%)	5724 (3.6%)	6807 (3.8%)
	Lumpectomy	109912 (63.3%)	114538 (63.5%)	100527 (62.8%)	113219 (63.9%)
	Mastectomy	58272 (33.6%)	59833 (33.2%)	53899 (33.7%)	57228 (32.3%)
	Unknown	265	311	254	339
Radiation Therapy	None	58967 (35.7%)	60887 (35.7%)	53002 (35.1%)	59823 (36.0%)
	Radiation post-lumpectomy	87404 (52.9%)	90683 (53.1%)	80152 (53.1%)	88715 (53.4%)
	Radiation post-mastectomy	18767 (11.4%)	19048 (11.2%)	17763 (11.8%)	17535 (10.6%)
	Unknown	3369	4103	3801	4749
Chemotherapy/ Immunotherapy (for stage I-III)	None	80115 (59.3%)	84403 (60.5%)	73515 (58.9%)	84702 (62.2%)
	Neoadjuvant	17871 (13.2%)	18745 (13.4%)	18918 (15.2%)	26365 (19.4%)
	Adjuvant	37009 (27.4%)	36262 (26.0%)	32382 (25.9%)	25182 (18.5%)
	Unknown	1626	1617	1565	1652
Endocrine Therapy (for stage I-III ER+)	None	12385 (11.3%)	12482 (11.0%)	10424 (10.3%)	15011 (13.7%)
	Neoadjuvant	3683 (3.3%)	4076 (3.6%)	7752 (7.7%)	5493 (5.0%)
	Adjuvant	93917 (85.4%)	97391 (85.5%)	83028 (82.0%)	89267 (81.3%)
	Unknown	4418	4884	4507	6513

Neoadjuvant systemic therapy (chemotherapy, immunotherapy, and/or endocrine therapy) trends for patients diagnosed with stage I-III breast cancer 2010-2021



- Increases in neoadjuvant systemic therapy use across all tumor subtypes and nearly all stages of disease
- >50% rates of use among HER2+ and ER-/HER2- stage II and III disease in recent years
- Significant increases also seen among ER- stage I breast cancers


of Surgeons.

Habermann et al, JACS 2025; 240(1):95-110

Short term outcomes among mastectomy patients diagnosed with breast cancer (DCIS, stages I-III) stratified by year of diagnosis (2018-2021).

	2018 (N=58,272)	2019 (N=59,833)	2020 (N=53,899)	2021 (N=57,228)
Surgical Inpatient Stay, Median (Q1, Q3)	1.0 (0.0, 1.0)	1.0 (0.0, 1.0)	1.0 (0.0, 1.0)	1.0 (0.0, 1.0)
Readmission to the Same Hospital within 30 Days of Surgical Discharge				
No readmission	55795 (96.8%)	57474 (97.0%)	51882 (97.2%)	54917 (96.8%)
Planned/Unplanned readmission	1855 (3.2%)	1794 (3.0%)	1504 (2.8%)	1828 (3.2%)
Unknown	622	565	513	483
Thirty-day Mortality				
No	57989 (99.9%)	59451 (99.9%)	53304 (100.0%)	NA
Yes	37 (0.1%)	36 (0.1%)	22 (0.0%)	
Unknown	246	346	573	
Ninety-day Mortality				
No	57716 (99.8%)	59020 (99.7%)	52675 (99.8%)	NA
Yes	139 (0.2%)	148 (0.3%)	117 (0.2%)	
Unknown	417	665	1107	

Overall survival for patients diagnosed with breast cancer (DCIS, stages I-IV) (2016-2020) stratified by stage or tumor subtype (biomarker, grade, and histology).



- Increasing disease stage, ER-/HER2- disease, and higher grade were associated with poorer overall survival


of Surgeons.

Habermann et al, JACS 2025; 240(1):95-110

Colon Cancer PUF 2021

- In 2021, 70,774 adult cases reported by 1,273 NCDB-participating facilities.
 - Represent an estimated **73.0%** of all colon cancers diagnosed in the US.
 - The total number of colon cancer cases in the NCDB 2004-2021 is 1,252,838 cases.
-
- Median age at diagnosis was 68 (IQR 57-78)
 - 50.0% of cases were in women, 50.0% in men
 - Other demographics
 - 73.9% White, 13.2% Black, 6.7% Spanish/Hispanic and 3.9% Asian
 - 32.9% Privately insured, 55.2% Medicare, and 8.0% Medicaid
 - Treatment facility information
 - 41.5% Comprehensive community, 28.4% Academic/research, 21.7% Integrated network and 8.5% Community

Proportion of patients diagnosed with colon cancer (stage I-IV) 2004-2021



- Overall stage distribution has remained stable across time

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Habermann et al, JACS 2025; 240(1):95-110

		2018 (N=72,778)	2019 (N=72,840)	2020 (N=64,344)	2021 (N=68,547)
Tumor Grade	Grade I	9702 (15.7%)	8917 (14.2%)	7832 (14.1%)	8166 (13.7%)
	Grade II	40599 (65.7%)	42366 (67.3%)	37165 (67.0%)	40522 (68.1%)
	Grade III/IV	11459 (18.6%)	11647 (18.5%)	10503 (18.9%)	10775 (18.1%)
	Unknown	11018	9910	8844	9084
Primary Site	Cecum	14812 (20.4%)	14891 (20.4%)	12859 (20.0%)	13527 (19.7%)
	Ascending colon	14287 (19.6%)	14139 (19.4%)	12495 (19.4%)	13155 (19.2%)
	Transverse colon	7178 (9.9%)	7086 (9.7%)	6342 (9.9%)	6825 (10.0%)
	Descending colon	4224 (5.8%)	4249 (5.8%)	3704 (5.8%)	3933 (5.7%)
	Sigmoid colon	18001 (24.7%)	18008 (24.7%)	15509 (24.1%)	17074 (24.9%)
	Colon NOS	14276 (19.6%)	14467 (19.9%)	13435 (20.9%)	14033 (20.5%)
Primary Surgery Type	No primary surgery	8172 (14.5%)	8474 (15.0%)	7874 (15.8%)	8316 (15.6%)
	Local tumor excision	1792 (3.2%)	1735 (3.1%)	1477 (3.0%)	1704 (3.2%)
	Colectomy	46370 (82.3%)	46347 (81.9%)	40522 (81.3%)	43122 (81.1%)
	Unknown	544	413	370	385


		2018 (N=72,778)	2019 (N=72,840)	2020 (N=64,344)	2021 (N=68,547)
MSI Tumor Marker	Stable	29516 (77.9%)	33083 (78.0%)	30924 (77.7%)	35031 (77.8%)
	Unstable Low	1636 (4.3%)	1624 (3.8%)	1444 (3.6%)	1459 (3.2%)
	Unstable High	6724 (17.8%)	7688 (18.1%)	7411 (18.6%)	8517 (18.9%)
	Unknown	34902	30445	24565	23540
KRAS Tumor Marker	Normal	6416 (56.9%)	6167 (56.2%)	5463 (56.5%)	6352 (56.7%)
	Abnormal	4869 (43.1%)	4798 (43.8%)	4200 (43.5%)	4853 (43.3%)
	Unknown	61493	61875	54681	57342
CEA tumor marker	Negative	21305 (49.7%)	22184 (49.5%)	19542 (48.2%)	21597 (48.4%)
	Positive	21552 (50.3%)	22609 (50.5%)	20963 (51.8%)	23008 (51.6%)
	Unknown	29921	28047	23839	23942

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Short term outcomes among colectomy patients stratified by year of diagnosis (2018-2021) in the NCDB.

	2018 (N=46,370)	2019 (N=46,347)	2020 (N=40,522)	2021 (N=43,122)
Surgical Inpatient Stay, Median (Q1, Q3)	4.0 (3.0, 7.0)	4.0 (3.0, 6.0)	4.0 (2.0, 6.0)	4.0 (2.0, 6.0)
Readmission to the Same Hospital within 30 Days of Surgical Discharge				
No readmission	43122 (94.0%)	43273 (94.2%)	37961 (94.5%)	40537 (94.7%)
Planned/Unplanned readmission	2772 (6.0%)	2671 (5.8%)	2217 (5.5%)	2271 (5.3%)
Unknown	476	403	344	314
Thirty-day Mortality				
No	44527 (97.2%)	44441 (97.4%)	38307 (96.7%)	NA
Yes	1304 (2.8%)	1201 (2.6%)	1297 (3.3%)	
Unknown	539	705	918	
Ninety-day Mortality				
No	43285 (95.1%)	43103 (95.2%)	36775 (94.2%)	NA
Yes	2249 (4.9%)	2150 (4.8%)	2253 (5.8%)	
Unknown	836	1094	1494	

Overall survival for colon cancer 2016-2020 stratified by stage or tumor marker (MSI, KRAS, and CEA).



- Increasing disease stage was associated with poorer overall survival
- Other factors associated with poorer overall survival included abnormal KRAS status, positive CEA, and stable MSI.


© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Habermann et al, JACS 2025; 240(1):95-110

Pancreas Cancer PUF 2021

- In 2021, 40,817 adult cases reported by 1,249 NCDB-participating facilities.
- Represent an estimated **76.4%** of all pancreatic cancers diagnosed in the US.
- The total number of pancreatic cancer cases in the NCDB 2004-2021 is 585,239 cases.
- Median age at diagnosis was 70 (IQR 62-77)
- 48.1% of cases were in women, 51.9% in men
- Other demographics
 - 74.9% White, 12.5% Black, 6.0% Spanish/Hispanic and 3.3% Asian
 - 25.8% Privately insured, 62.4% Medicare, and 6.6% Medicaid
- Treatment facility information
 - 34.5% Comprehensive community, 38.9% Academic/research, 20.2% Integrated network and 5.0% Community

Proportion of patients diagnosed with pancreas cancer 2004-2021



- Stage IV disease is most common stage at diagnosis of pancreatic cancer
- Increase in the proportion of patients presenting with stage I disease from 2004-2021

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.


Habermann et al, JACS 2025; 240(1):95-110

		2018 (N=41,097)	2019 (N=42,403)	2020 (N=41,194)	2021 (N=40,442)
Grade	Grade I	3218 (21.5%)	3355 (21.0%)	3093 (19.9%)	3122 (19.9%)
	Grade II	6587 (44.0%)	7167 (44.9%)	7040 (45.2%)	7374 (46.9%)
	Grade III/IV	5149 (34.4%)	5423 (34.0%)	5435 (34.9%)	5228 (33.2%)
	Unknown	26143	26458	25626	24718
Histology	Adenocarcinoma	33014 (80.3%)	34304 (80.9%)	33394 (81.1%)	32961 (81.5%)
	Neuroendocrine	1449 (3.5%)	1516 (3.6%)	1439 (3.5%)	1320 (3.3%)
	Other	6634 (16.1%)	6583 (15.5%)	6361 (15.4%)	6161 (15.2%)
Primary Site	Head	20267 (49.3%)	20868 (49.2%)	20224 (49.1%)	19529 (48.3%)
	Body	5990 (14.6%)	6088 (14.4%)	5956 (14.5%)	6061 (15.0%)
	Tail	6554 (15.9%)	6901 (16.3%)	6615 (16.1%)	6525 (16.1%)
	Other	8286 (20.2%)	8546 (20.2%)	8399 (20.4%)	8327 (20.6%)
Primary Surgery Type	No primary surgery	31030 (76.1%)	32110 (76.4%)	31553 (77.3%)	31043 (77.5%)
	Local excision	162 (0.4%)	152 (0.4%)	136 (0.3%)	133 (0.3%)
	Pancreatectomy	9585 (23.5%)	9751 (23.2%)	9141 (22.4%)	8869 (22.1%)
	Unknown	320	390	364	397

Short term outcomes among pancreatectomy patients stratified by year of diagnosis (2018-2021)

	2018 (N=7,462)	2019 (N=7,557)	2020 (N=7,058)	2021 (N=6,810)
Surgical Inpatient Stay, Median (Q1, Q3)	7.0 (5.0, 10.0)	6.0 (5.0, 9.0)	6.0 (5.0, 9.0)	6.0 (4.0, 8.0)
Readmission to the Same Hospital within 30 Days of Surgical Discharge				
No readmission	6708 (90.8%)	6890 (91.9%)	6444 (92.1%)	6240 (92.5%)
Planned/Unplanned readmission	677 (9.2%)	604 (8.1%)	554 (7.9%)	508 (7.5%)
Unknown	77	63	60	62
Thirty-day Mortality				
No	7273 (97.9%)	7363 (98.0%)	6805 (97.7%)	NA
Yes	155 (2.1%)	154 (2.0%)	159 (2.3%)	
Unknown	34	40	94	
Ninety-day Mortality				
No	7078 (95.6%)	7131 (95.5%)	6558 (95.5%)	NA
Yes	326 (4.4%)	337 (4.5%)	306 (4.5%)	
Unknown	58	89	194	

Overall survival for patients diagnosed with pancreas cancer stratified by stage, anatomic location, tumor grade, and histology.




- Increasing disease stage was associated with poorer overall survival
- Stage IV disease has few long-term survivors
- Both low grade disease and neuroendocrine histology have improved long-term survival

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Habermann et al, JACS 2025; 240(1):95-110

Chemotherapy use trends during any time of treatment



- Increase in the use of chemotherapy during any time of treatment among stage I pancreatic tumors

Takeaways

- First Annual Report of the American College of Surgeons Cancer Research Program with an overview of the 2021 National Cancer Database Adult PUF file was introduced
- In depth descriptions of the breast, colon, and pancreas cancer PUFs
- Provide data and understanding of recent cancer diagnoses, patient demographics, treatments, and outcomes

Next Steps

- Future reports will include new data along with in-depth descriptions of other cancer sites
- Annual report from 2022 PUF currently in preparation – with in-depth descriptions of prostate, esophagus, melanoma tumor sites
- Annual reports for both the 2022 PUF and 2023 PUF anticipated to be available prior to ACS Cancer Conference next year

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Thank You




Judy C. Boughey
Chair of ACS CRP



Elizabeth Habermann
Chair of ACS CRP
Cancer Data
Modelling Committee




Jennifer Plichta – Breast SME



Bryan Palis – NCDB manager



Nabil Wasif – Colon and
Pancreas SME



Ron Weigel – Chair
ACS Cancer Programs

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.